144 related articles for article (PubMed ID: 32528567)
1. Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin.
Luengsupabul S; Methavigul K; Methavigul R
J Arrhythm; 2020 Jun; 36(3):425-429. PubMed ID: 32528567
[TBL] [Abstract][Full Text] [Related]
2. Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study.
Al-Najar M; Al-Nusair M; Alrabadi N; Alawaisheh I; Alawaisheh T; Jarrah M; Alzoubi KH; Njem S; Hamoudeh A
Vasc Health Risk Manag; 2023; 19():145-155. PubMed ID: 36968249
[TBL] [Abstract][Full Text] [Related]
3. Optimal INR level in Thai atrial fibrillation patients who were receiving warfarin for stroke prevention in Thailand.
Methavigul K; Boonyapisit W
J Med Assoc Thai; 2014 Dec; 97(12):1274-80. PubMed ID: 25764634
[TBL] [Abstract][Full Text] [Related]
4. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.
Bisson A; Bodin A; Clementy N; Bernard A; Babuty D; Lip GYH; Fauchier L
Int J Cardiol; 2018 Jun; 260():93-98. PubMed ID: 29540261
[TBL] [Abstract][Full Text] [Related]
5. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study.
Melgaard L; Jensen M; Overvad TF; Larsen TB; Lip GYH; Nielsen PB
Int J Clin Pract; 2020 Oct; 74(10):e13589. PubMed ID: 32574395
[TBL] [Abstract][Full Text] [Related]
7. Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand.
Krittayaphong R; Kunjara-Na-Ayudhya R; Ngamjanyaporn P; Boonyaratavej S; Komoltri C; Yindeengam A; Sritara P; Lip GYH; For The Cool-Af Investigators
J Geriatr Cardiol; 2020 Oct; 17(10):612-620. PubMed ID: 33224180
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; de Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B
Thromb Haemost; 2017 Dec; 117(12):2215-2236. PubMed ID: 29212110
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy and safety of antithrombotic therapy with warfarin in nonrheumatic atrial fibrillation].
; Hu DY
Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):800-3. PubMed ID: 17217741
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease.
Melgaard L; Overvad TF; Jensen M; Lip GYH; Larsen TB; Nielsen PB
JACC Clin Electrophysiol; 2020 Dec; 6(13):1672-1682. PubMed ID: 33334446
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
[TBL] [Abstract][Full Text] [Related]
12. INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation.
Chung JE; Choi YR; Seong JM; La HO; Gwak HS
Int J Clin Pharm; 2015 Dec; 37(6):1038-46. PubMed ID: 26068570
[TBL] [Abstract][Full Text] [Related]
13. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?
You JH; Chan FW; Wong RS; Cheng G
Br J Clin Pharmacol; 2005 May; 59(5):582-7. PubMed ID: 15842557
[TBL] [Abstract][Full Text] [Related]
14. Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study.
Ohgushi A; Ohtani T; Nakayama N; Asai S; Ishii Y; Namiki A; Akazawa M; Echizen H
J Pharm Health Care Sci; 2016; 2():2. PubMed ID: 26819747
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation.
Kang F; Ma Y; Cai A; Cheng X; Liu P; Kuang J; Mai Z; Mai W
Am J Cardiol; 2021 Mar; 142():74-82. PubMed ID: 33307015
[TBL] [Abstract][Full Text] [Related]
17. Optimal INR level for warfarin therapy after mechanical mitral valve replacement.
Kamthornthanakarn I; Krittayaphong R
BMC Cardiovasc Disord; 2019 Apr; 19(1):97. PubMed ID: 31023235
[TBL] [Abstract][Full Text] [Related]
18. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation.
Yasaka M; Minematsu K; Yamaguchi T
Intern Med; 2001 Dec; 40(12):1183-8. PubMed ID: 11813841
[TBL] [Abstract][Full Text] [Related]
19. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Pokorney SD; Holmes DN; Thomas L; Fonarow GC; Kowey PR; Reiffel JA; Singer DE; Freeman JV; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli GV; Ezekowitz MD; Piccini JP; Peterson ED;
JAMA Cardiol; 2019 Aug; 4(8):756-764. PubMed ID: 31268487
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study.
Naganuma M; Shiga T; Sato K; Murasaki K; Hashiguchi M; Mochizuki M; Hagiwara N
Thromb Res; 2012 Jul; 130(1):21-6. PubMed ID: 22137743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
